-
Validated Image Analysis for accurate biomarker quantification.
-
Complete Digital Pathology for remote Case Review, Teaching & Research Pathology
-
Dedicated team delivering Lymphoma, ALK, ROS1 NSCLC & Bladder Cancer FISH
-
Specialist Breast, Gastric & Lung Cancer Biomarker IHC testing services now available
-
Providing accredited IHC, ISH, Molecular & Digital Pathology services throughout the UK and overseas
-
Cutting edge research in Next Generation Sequencing for personalised medicine applications
-
Highly Sensitive Mutation Analysis Service for EGFR, KRAS & BRAF
Latest News
19/04/23 Service Provision
The HSL-AD service is able to take in additional referral work to help maintain services under pressure. Please contact the laboratory if you are planning on referring a significant amount of additional work.
30/03/20 HSL Advanced Diagnostics Laboratory Move
We are pleased to inform you that from 30th March, 2020 HSL-Advanced Diagnostics will operate from our new and permanent location at 60 Whitfield Street Read more...
30/06/18 Advanced Diagnostics Validates New ROS1 IHC Assay for NSCLC
Following approval from NICE to allow access to Crizotonib for ROS1 positive patients with NSCLC, Advanced Diagnostics have made available a validated ROS1 IHC assay to all referring clients. Read more...
26/04/18 Advanced Diagnostics joins Health Services Laboratories pathology joint venture organisation
From the 1st May 2018 we are pleased to announce the creation of HSL Advanced Diagnostics. Read more...
27/10/17 Advanced Diagnostics are please to inform that we have received accreditation by UKAS to ISO15189:2012 standards
Advanced Diagnostics are please to inform that we have received accreditation by UKAS to ISO15189:2012 standards. Our UKAS customer number is 9007 and our scope of accreditation can be found here. Read more...
14/12/16 Advanced Diagnostics Accreditation Status
After a successful UKAS assessment on the 13th & 14th of December 2016, the Advanced Diagnostics laboratories are very happy to announce that we are currently "Recommended for Accreditation" to UKAS/ISO15189:2012 standards. Read more...
25/08/16 PD-L1 22C3 EAMS Reference Laboratory
HSL Advanced Diagnostics is now offering PD-L1 IHC testing using the Dako pharmDx 22C3 companion diagnostic for Pembrolizumab. Read more...
28/01/13 Advanced Diagnostics Validates New ALK IHC Assay for NSCLC
Advanced Diagnostics validates the new Roche Tissue Diagnostics ALK IHC assay for use in Non Small Cell Lung Cancer (NSCLC) patients for whom Crizotinib (Xalkori, Pfizer) is being considered. Read more...
24/10/12 Advanced Diagnostics Begins Centralised Testing for Major Clinical Trial.
Now open for recruitment, OPTIMA is a partially-blind randomised trial designed to compare clinical and economic outcomes of standard chemotherapy treatment with biomarker-directed allocation to chemotherapy or no chemotherapy in women with ER positive, HER2 negative breast cancer and either axillary node involvement or larger tumours'. Read more...
22/05/12 Advanced Diagnostics Attends Parliamentary Briefing on Targeted Cancer Diagnostics & Personalised Medicine
Representatives from Advanced Diagnostics/London Cancer & BCUK attend parliamentary briefing to discuss the importance of targeted testing and personalised medicine, with a specific focus on colorectal cancer, KRAS testing and Cetuximab. Read more...
22/05/12 Advanced Diagnostics Supports use of new Roche HER2 Teaching Resource
Roche unveil new HER2 teaching resource. The 'HER2testing' web resource supports interpretation of HER2 testing in breast and gastric cancer in all areas including IHC, CISH, FISH and DDISH and provides a valuable resource for scientists and pathologists. Read more...
22/05/12 Advanced Diagnostics Adopts Roche Companion Diagnostics Testing Platform
Advanced Diagnostics has chosen to adopt Roche Pathway HER2 (4B5) on the Benchmark ULTRA automated staining system for use in breast and gastric cancer HER2 testing applications. Read more...